191 related articles for article (PubMed ID: 26232270)
21. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
22. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
23. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.
Hiraike M; Hiraki Y; Misumi N; Hanada K; Tsuji Y; Kamimura H; Karube Y; Kashiwabara K
Cancer Chemother Pharmacol; 2012 Mar; 69(3):845-8. PubMed ID: 22194156
[TBL] [Abstract][Full Text] [Related]
25. Generation of evidence-based carboplatin dosing guidelines for neonates and infants.
Barnett S; Makin G; Tweddle DA; Osborne C; Veal GJ
Br J Cancer; 2023 Nov; 129(11):1773-1779. PubMed ID: 37816842
[TBL] [Abstract][Full Text] [Related]
26. [Safe and effective administration of carboplatin-based chemotherapy in a patient undergoing hemodialysis with cancer of unknown primary by monitoring observed AUC of carboplatin-a case report].
Kondo M; Kuroda J; Ikai Y; Hayashi R; Uegaki S; Yoshida T; Yoshida A; Komatsu H; Kimura K
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1749-52. PubMed ID: 23152033
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature.
Kamei K; Sako M; Ishikawa T; Sato M; Ogura M; Uno T; Kiyotani C; Mori T; Tanaka H; Ito S; Nakamura H
Ther Apher Dial; 2015 Oct; 19(5):491-6. PubMed ID: 25916242
[TBL] [Abstract][Full Text] [Related]
28. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.
Thomas F; Veal GJ; El Balkhi S; Lafont T; Picard N; Brugières L; Chatelut E; Piguet C
Cancer Chemother Pharmacol; 2018 Aug; 82(2):361-365. PubMed ID: 29922990
[TBL] [Abstract][Full Text] [Related]
30. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetic and therapeutic monitoring of gentamicin serum concentration in neonates].
Kaminska E; Piekarczyk A; Prokopczyk J; Zimak J; Sosnowska K; Taljanski W
Med Wieku Rozwoj; 2001; 5(2):141-7. PubMed ID: 11679678
[TBL] [Abstract][Full Text] [Related]
33. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective.
Roberts E; Mogg JAW; Barnfield M; Veal GJ
Pediatr Hematol Oncol; 2020 Apr; 37(3):235-244. PubMed ID: 31941404
[TBL] [Abstract][Full Text] [Related]
34. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.
Jehanne M; Lumbroso-Le Rouic L; Savignoni A; Aerts I; Mercier G; Bours D; Desjardins L; Doz F
Pediatr Blood Cancer; 2009 May; 52(5):637-43. PubMed ID: 19148943
[TBL] [Abstract][Full Text] [Related]
35. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Barnett S; Kong J; Makin G; Veal GJ
Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
Veal GJ; Cole M; Errington J; Pearson AD; Gerrard M; Whyman G; Ellershaw C; Boddy AV
Cancer Chemother Pharmacol; 2010 May; 65(6):1057-66. PubMed ID: 19701749
[TBL] [Abstract][Full Text] [Related]
37. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
38. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
39. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
Ai Zheng; 2006 Dec; 25(12):1550-2. PubMed ID: 17166384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
